Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop.
The complement system is a humoral effector in the innate immune system. Three activation pathways exist in the complement system, known as the classical pathway, the lectin pathway and the alternative pathway. Dysfunction of lectin pathway activation is caused by MBL deficiency. MBL deficiency in a cohort of healthy Caucasian blood bank donors was investigated with MBL genotyping and MBL plasma concentration. Recognition of the yeast-derived zymosan by MBL was investigated with Western blot. The involvement of the alternative pathway amplification loop in enhancing MBL-mediated opsonization of zymosan was investigated in a novel opsonophagocytosis assay for flow cytometry. Sera deficient for MBL, factor D or properdin were tested, and purified MBL, factor D or properdin were used to recover opsonization. The optimal receiver-operator characteristic (ROC) cut-off value for dividing the Caucasian cohort in MBL-sufficient and MBL-deficient was calculated at 0.7 microg/ml. Thirty-eight percent of the group had concentrations below 0.7 microg/ml. Zymosan eluates opsonized with MBL-sufficient sera contain high oligomers of MBL, while eluates from MBL-deficient donors contained hardly any MBL. The MBL-, factor D- and properdin-deficient sera showed reduced opsonophagocytosis by human control neutrophils, as compared to normal MBL-sufficient sera. This reduction in opsonization was restored to normal levels by addition of purified MBL, factor D and properdin. The absence of opsonization in the factor D- and properdin-deficient sera, but presence in normal serum after blocking with anti-C1q-F(ab)2 and anti-MBL-F(ab)2, demonstrates the involvement of the amplification loop in MBL-initiated zymosan opsonization, even at very low serum concentrations (up to 3%, v/v). In conclusion, our data demonstrate that the MBL-mediated route of complement activation depends on the alternative pathway amplification loop for optimal opsonization of zymosan.
Brouwer
Nannette
N
Sanquin Research-Academic Medical Centre Landsteiner Laboratory, Amsterdam, The Netherlands. n.brouwer@sanquin.nl
Dolman
Koert M
KM
van Zwieten
Rob
R
Nieuwenhuys
Ed
E
Hart
Margreet
M
Aarden
Lucien A
LA
Roos
Dirk
D
Kuijpers
Taco W
TW
D015331:Cohort Studies; D015922:Complement C1q / Q000032:analysis / Q000276:immunology; D011416:Complement Factor D / Q000172:deficiency / Q000276:immunology; D037582:Complement Pathway, Mannose-Binding Lectin / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology / Q000494:pharmacology; D037601:Mannose-Binding Lectin / Q000097:blood / Q000172:deficiency / Q000276:immunology*; D009504:Neutrophils / Q000166:cytology / Q000276:immunology*; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology*; D044465:White People; D015054:Zymosan / Q000276:immunology / Q000494:pharmacology
D007140:Immunoglobulin Fab Fragments; D037601:Mannose-Binding Lectin; D015922:Complement C1q; D015054:Zymosan; D011416:Complement Factor D